Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Poseida Therapeutics

Poseida Therapeutics
2015 FOUNDED
PRIVATE STATUS
71-80 EMPLOYEES
IPO LATEST DEAL TYPE (Cancelled)
$115M LATEST DEAL AMOUNT
11 INVESTORS
Description

Developer of non-viral gene engineering technologies intended to create cell therapies with the capacity to cure cancer. The company's technologies include stem memory T cells, Cas-CLOVER gene editing and CAR-T tools which are based on proprietary genome engineering, enabling medical practitioners to treat liver disorders and cancer with increased safety, tolerability and scalability.

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 9390 Towne Center Drive
  • Suite 200
  • San Diego, CA 92121
  • United States

+1 (858) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Poseida Therapeutics’s full profile, request a free trial.

Poseida Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. IPO 04-Jan-2019 $115M Cancelled Clinical Trials - Phase 2
7. Later Stage VC (Series C) 22-Apr-2019 00000 00000 00000 Completed Clinical Trials - Phase 2
6. Early Stage VC (Series B) 03-Apr-2018 000.00 000.00 00000 Completed Clinical Trials - Phase 2
5. Grant 000 000.00 Completed Clinical Trials - Phase 2
4. Grant 26-Oct-2017 000.00 000.00 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series A1) 02-Aug-2017 000.00 000.00 00000 Completed Clinical Trials - Phase 2
2. Corporate (Series A) 14-Dec-2015 $30M $30M 0000 Completed Clinical Trials - Phase 2
1. Accelerator/Incubator 01-Jun-2015 Completed Clinical Trials - Phase 2
To view this company’s complete deal history including valuation and funding, request access »

Poseida Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series C 00,000,000 00.000000 000.00 000.00 00 000.00 000
Series B 0,000,000 00.000000 00.00 00.00 00 00.00 0.000
Series A1 3,370,263 $0.000100 $3.43 $3.43 1x $3.43 6.04%
Series A 9,696,798 $0.000100 $3.43 $3.43 1x $3.43 17.38%
To view this company’s complete Cap Table, request access »

Poseida Therapeutics Competitors (44)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sangamo Therapeutics Formerly VC-backed Richmond, CA 000 000.00 00000000 000.00
0000000 Venture Capital-Backed Philadelphia, PA 00000 00000000000 00000
000000000 Venture Capital-Backed Rockville, MD 000.00 0000000000 0 000.00
00000000 Formerly VC-backed Munich, Germany 000.00 000000&0 000.00
000000 Venture Capital-Backed Utrecht, Netherlands 00.000 00000000000 00.000
To view this company’s complete list of competitors, request access »

Poseida Therapeutics Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Aisling Capital Venture Capital Minority 000 0000 000000 0
Novartis Pharma Corporation Minority 000 0000 000000 0
Pentwater Capital Management Hedge Fund Minority 000 0000 000000 0
Perceptive Advisors Hedge Fund Minority 000 0000 000000 0
Boxer Capital PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »

Poseida Therapeutics Executive Team (10)

Name Title Board
Seat
Contact
Info
Eric Ostertag Ph.D Chief Executive Officer, Board Member & President
Mark Gergen JD Chief Business Officer, Chief Financial Officer & Board Member
Paiman Ghoroghchian Ph.D Chief Technology Officer
Kristin Martin Chief Human Resources Officer
Devon Shedlock Ph.D Vice President, Preclinical Development

3 Former Executives

You’re viewing 5 of 10 executives. Get the full list »

Poseida Therapeutics Board Members (13)

Name Representing Role Since Contact
Info
Catherine Mackey Ph.D Self Board Member 000 0000
David Hirsch Ph.D Longitude Capital Board Member 000 0000
Eric Ostertag Ph.D Poseida Therapeutics Chief Executive Officer, Board Member & President 000 0000
John Schmid Self Board Member 000 0000
Marcea Lloyd JD Self Board Member 000 0000

5 Former Board Members

You’re viewing 5 of 13 board members. Get the full list »